AI Blood Tests and Smart Wearables: How Technology Is Learning to Detect Illness Before Symptoms Appear

SEO Title: AI Blood Tests and Smart Wearables: Can Technology Detect Diseases Earlier?

Meta Description: Discover how AI blood tests, smart wearables and automated medical screening detect early signs of cancer, heart disease, glaucoma and infections—and why detection is not the same as diagnosis.

URL Slug: ai-blood-tests-smart-wearables-early-disease-detection

Keywords: AI blood tests, early disease detection, AI cancer screening, smart health wearables, medical artificial intelligence, liquid biopsy, multi-cancer early detection, wearable health sensors, AI diagnostics, predictive healthcare.

The Future of Healthcare May Begin Before You Feel Sick

Imagine waking up, putting on your smartwatch and checking your usual morning health dashboard. Your heart rate looks normal. You slept reasonably well. Nothing feels unusual.

But something has changed.

Over the past several nights, your resting heart rate has gradually increased. Your sleep patterns have become less stable. Your body temperature is slightly higher than its normal range. None of these changes is dramatic enough to make you feel ill, but an artificial intelligence system analysing your measurements notices a pattern.

It sends an alert suggesting that your physiological measurements have changed.

Elsewhere, in a laboratory, a small blood sample is being examined for something even harder to see: fragments of genetic material that may have been released by abnormal cells. An AI-supported system compares the molecular signals with patterns learned from thousands of previous samples. It identifies a combination of features that deserves further investigation.

Neither system has necessarily discovered a disease. Neither can automatically tell someone what illness they have.

But both may have identified an early warning worth examining.

This is the central promise of a rapidly developing area of healthcare technology: finding biological changes before they become obvious symptoms, and sometimes before conventional medical pathways would otherwise investigate them.

The idea is attracting attention across several areas of medical research. In its November 2026 science trends roundup, published on November 2, Trend Hunter highlighted AI cancer blood tests, modular health wearables, automated glaucoma testing and rapid infection diagnostic platforms. These developments illustrate a wider movement towards more accessible, data-driven and potentially earlier medical assessment.

However, the excitement deserves a careful explanation. A blood test that detects a possible cancer signal is not necessarily a test that diagnoses cancer. A smartwatch that identifies an unusual heartbeat is not the same as a cardiologist confirming a heart condition. An AI system that flags an eye scan is not automatically replacing an ophthalmologist.

Understanding that difference is essential to understanding where medical AI really stands.

1. Why Detecting Disease Earlier Could Change Medicine

Traditional healthcare often follows a sequence: a person notices a symptom, seeks medical attention, undergoes examinations, and receives tests that help identify the cause.

This approach remains essential. However, it has one limitation: some diseases develop quietly.

A tumour may release molecular material into the bloodstream long before it causes pain. An irregular heart rhythm may occur occasionally without producing noticeable symptoms. Glaucoma can damage the optic nerve gradually while vision initially appears normal. Some infections produce measurable changes in the immune system before a person recognises that they are becoming ill.

Technology is beginning to explore whether these invisible changes can be measured earlier.

There are three major reasons this matters.

First, some diseases are easier to treat when discovered early. In cancer, for example, the location, size and extent of a tumour can influence treatment options. Finding a cancer before it spreads can sometimes make treatment less complicated and improve the likelihood of successful outcomes.

Second, continuous monitoring can reveal changes that a single appointment might miss. A smartwatch recording measurements throughout the day has access to a different type of information from a medical examination lasting fifteen minutes.

Third, automated analysis can examine more information than a person could realistically interpret manually. A laboratory might measure thousands of molecular features. A wearable might generate millions of physiological measurements over several months. Machine-learning systems can help identify combinations and trends within these large datasets.

But there is an important qualification.

Finding an abnormality earlier does not automatically mean saving a life. The finding must be reliable, clinically meaningful and connected to an effective treatment or intervention.

The National Cancer Institute explains that screening can produce false positives, false negatives and overdiagnosis. Some abnormalities discovered through screening would never have caused symptoms or affected someone's lifespan.

The objective, therefore, is not simply to discover more abnormalities. It is to discover the right abnormalities at the right time.

2. What Do AI Blood Tests Actually Measure?

Blood samples and medical laboratory testing — Blood samples being prepared for laboratory testing. Image source: National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH).

Blood is one of the most information-rich substances in the human body.

It transports oxygen, nutrients, hormones, immune cells, proteins and waste products. It also carries molecular material released by tissues throughout the body.

When cells grow, divide, become damaged or die, they can release biological material into circulation. Some of this material can provide clues about what is happening inside an organ.

AI-assisted blood tests attempt to recognise meaningful combinations of these signals.

However, different tests measure different things. There is no single universal AI blood test that can reliably identify every disease.

2.1 Circulating tumour DNA: searching for traces of cancer

One of the most interesting technologies is called circulating tumour DNA, commonly abbreviated as ctDNA.

When cancer cells die or release material, fragments of their DNA can enter the bloodstream. These fragments become part of the broader collection of cell-free DNA, or cfDNA, circulating in plasma.

Most cell-free DNA comes from normal cells. The challenge is identifying the relatively small proportion that may originate from a tumour.

Think of a crowded railway station.

Thousands of people move through the station every minute. A small number belong to a particular group wearing an unusual colour. Finding them requires more than simply counting everyone who passes through. It requires identifying specific characteristics that distinguish one group from another.

Cancer blood testing faces a similar challenge.

Laboratories can examine:

Genetic mutations associated with particular cancers.
Changes in DNA methylation.
Patterns in how DNA fragments are broken apart.
The relative abundance of certain molecular fragments.
Specific proteins released by abnormal cells.

DNA methylation is particularly interesting.

Methylation involves chemical modifications to DNA that influence how genes are regulated. Different tissues have characteristic methylation patterns. Some cancers develop abnormal patterns that can be detected in circulating DNA.

An algorithm can examine these patterns and estimate whether the sample contains a molecular signature associated with cancer.

Some approaches also attempt to predict the tissue or organ from which the signal originated.

This is potentially valuable because a blood sample is relatively easy to collect, while investigating every organ individually would require multiple procedures.

But a molecular signature is not the same as a confirmed tumour.

A positive result means that the test has found a pattern that warrants investigation. It does not establish the exact location, type or clinical significance of a cancer.

The US National Cancer Institute explains that multi-cancer detection tests can measure tumour DNA, circulating tumour cells, DNA methylation, DNA fragmentation, RNA, proteins and other biological signals.

2.2 Protein biomarkers: measuring the body's chemical messages

DNA is not the only source of information.

Proteins perform many of the body's essential functions. They help regulate inflammation, transport substances, control biological reactions and coordinate communication between cells.

Some diseases change the concentration of particular proteins in the blood.

For example, inflammation can increase certain proteins. Some tumours produce or influence proteins that can be measured as biomarkers.

A biomarker is a measurable biological characteristic associated with a physiological process, disease or response to treatment.

AI can analyse several biomarkers together rather than interpreting each one independently.

Imagine a building with several security sensors.

One sensor detects movement. Another detects temperature. A third detects smoke. Any one sensor might produce an unusual reading for an innocent reason. However, when several sensors activate together in a particular sequence, the probability of a genuine incident may increase.

AI-supported biomarker analysis follows a similar principle.

A combination of signals may be more informative than a single measurement.

Nevertheless, many biomarkers are not specific to one disease. Inflammation, infection, injury and other conditions can influence the same proteins.

2.3 RNA and immune-system signals

Another important area involves RNA.

RNA molecules help cells use genetic instructions to produce proteins. Changes in RNA expression can reveal how cells are responding to their environment.

An infection, for example, can activate particular immune pathways. The body may increase or decrease the expression of specific genes as it responds to bacteria or viruses.

Scientists can measure selected RNA molecules and use machine learning to interpret the resulting pattern.

This is particularly interesting because a test does not always need to detect the invading organism directly.

Sometimes, the body's response provides useful information about the likely cause of illness.

2.4 What AI adds to a blood test

It is important to separate the laboratory measurement from the artificial intelligence.

The laboratory equipment collects or measures biological information. The algorithm analyses that information and produces an interpretation.

A simplified process looks like this:

A blood sample is collected.
The laboratory separates or prepares the relevant material.
Instruments measure selected DNA, RNA, proteins or other biomarkers.
Software converts the measurements into numerical features.
An AI model compares the features with patterns learned during development and validation.
The system produces a risk estimate, classification or recommendation for further investigation.
A clinician interprets the result in the context of other evidence.

Machine learning can be useful because biological signals are complicated.

A tumour may not produce one unmistakable marker. Instead, it may produce a collection of small changes across many measurements.

An algorithm can learn that certain combinations are associated with a particular outcome.

However, this ability depends on the quality of the training data.

If an algorithm learns from samples that do not adequately represent the population in which it will eventually be used, its performance may decline. It can also mistake unrelated biological changes for disease-related patterns.

AI does not eliminate the uncertainty inherent in the original measurements.

3. The Real-World Test: Can One Blood Sample Detect Multiple Cancers?

Multi-cancer early detection tests, also known as MCED or MCD tests, represent one of the most closely watched applications of AI-assisted laboratory science.

The basic concept is straightforward.

Instead of ordering separate screening tests for different cancers, a laboratory analyses one blood sample for molecular signals associated with several cancer types.

Some tests also attempt to predict where a possible cancer originated.

One prominent example is the Galleri test, which was evaluated in the large NHS-Galleri trial in England.

The trial is particularly important because it moved beyond asking whether a laboratory could identify cancer-related signals. Researchers wanted to know whether using the test could actually change when cancers were diagnosed.

3.1 What did the NHS-Galleri trial investigate?

The randomised trial involved 142,250 participants aged approximately 50 to 77.

Participants were assigned to two groups:

An intervention group whose blood samples were tested using the multi-cancer detection system.
A control group that continued with usual healthcare without receiving the experimental screening result.

The researchers examined whether adding annual blood testing to standard healthcare reduced the number of advanced cancers diagnosed.

The trial examined 12 prespecified cancer types, including lung, pancreatic, colorectal, ovarian, stomach and liver cancers.

The results were published in the New England Journal of Medicine in September 2026.

3.2 What did the researchers discover?

The results were more complicated than the promise of a simple blood test might suggest.

The main objective was not achieved.

Researchers did not observe a statistically significant reduction in the overall incidence of stage III and stage IV cancers in the screening group compared with the control group.

The reported incidence-rate ratio was 1.03, with a 95% confidence interval of 0.92 to 1.14.

However, there were encouraging secondary observations.

The incidence-rate ratio for stage IV cancers alone was 0.86, with a 95% confidence interval of 0.74 to 1.00. The trial also recorded more early-stage diagnoses among people receiving the screening test.

These observations deserve further investigation, but they do not overturn the fact that the primary endpoint was not met.

3.3 How accurate was the blood test?

A separate analysis published in Nature Medicine examined the test's performance across three annual screening rounds.

The findings provide an important illustration of both the potential and the limitations of multi-cancer detection.

Measurement	First screening round
Participants tested	70,325
Positive results	722
Positive-result rate	1.03%
Positive results followed by a primary cancer diagnosis	419
Positive predictive value	58.0%
Specificity	99.56%
Episode sensitivity	37.2%

Across the three rounds, specificity remained approximately 99.5% to 99.6%.

However, episode sensitivity for all cancers ranged from 26.7% to 37.2%.

The positive predictive value also declined across the three rounds, from 58.0% in the first round to 45.8% in the third.

These are important distinctions. A test can be highly specific while still missing a considerable proportion of cancers.

The negative predictive value was approximately 99%, but this figure must not be interpreted as proof that a negative result excludes cancer. The sensitivity results show why that would be misleading.

3.4 Why this trial matters

The NHS-Galleri results demonstrate something important about medical innovation.

There is a difference between proving that a technology can detect a biological signal and proving that using it improves health outcomes.

The test identified cancers in some participants who might otherwise have been diagnosed through another route. It also showed that predicting a cancer signal can be possible with relatively high specificity.

But the crucial question remains: does introducing the test into routine screening reduce advanced disease and ultimately prevent deaths?

That requires longer follow-up and further clinical evidence.

As of November 5, 2026, the US National Cancer Institute states that no multi-cancer detection tests have received FDA authorisation. Some tests are offered as laboratory-developed tests, but this does not establish that they have demonstrated a population-level health benefit.

These tests should therefore be understood as an emerging technology, not a replacement for established cancer screening.

4. Smart Wearables: Turning the Human Body into a Continuous Data Stream

Person wearing a smartwatch for everyday health monitoring — A person wearing and adjusting a smartwatch, illustrating the growing role of wearable technology in everyday health monitoring. Photographer: Crew, originally published on Pixabay. Source: Wikimedia Commons. Licence: CC0 1.0.

Blood tests provide a snapshot of biological information at a particular moment.

Wearable technology offers something different: repeated measurements over time.

A smartwatch, smart ring, fitness band or medical patch can collect physiological information while someone works, sleeps, walks or rests.

Instead of asking only what the body is doing during a medical appointment, researchers can investigate how it behaves throughout ordinary life.

This is one reason modular health wearables are attracting attention.

A modular system can combine different sensor components according to the information required. One configuration might prioritise cardiac activity, another movement and temperature, and another biochemical measurements.

The technology is not necessarily one universal smartwatch. It is an approach to building monitoring systems around specific health questions.

4.1 What does a smartwatch actually measure?

The most important point is that a wearable usually measures physical or electrical signals. It then uses mathematical models to estimate physiological characteristics.

Here are the main technologies.

Photoplethysmography (PPG)

This optical sensor shines light into the skin and measures changes in the light reflected back.

Blood absorbs light, and the amount of blood in small vessels changes with each heartbeat. The sensor detects these variations and estimates the pulse.

PPG is commonly used to estimate:

Heart rate.
Pulse-rate variability.
Some measures of breathing rate.
Peripheral oxygen saturation on supported devices.

Electrocardiography (ECG)

ECG sensors measure electrical activity associated with the heartbeat.

A smartwatch with ECG electrodes can record a short electrical tracing, sometimes lasting approximately 30 seconds.

This can help identify patterns associated with an irregular rhythm, including atrial fibrillation.

It is not equivalent to a complete clinical 12-lead ECG.

Accelerometers and gyroscopes

These sensors measure movement, acceleration and orientation.

They can help estimate:

Physical activity.
Walking patterns.
Sleep-related movement.
Changes in mobility.
Falls or unusual motion.

Temperature sensors

Some wearables monitor skin-temperature changes.

Skin temperature is not identical to core body temperature. It can be influenced by the surrounding environment, clothing, circulation and activity.

Nevertheless, repeated measurements can provide useful information about changes from an individual's usual pattern.

Pulse oximetry

Some wearables estimate oxygen saturation using optical measurements.

The underlying principle involves analysing how light is absorbed differently by oxygenated and deoxygenated haemoglobin.

However, accuracy can vary with movement, skin characteristics, device positioning and other factors. Consumer devices should not automatically be treated as equivalent to clinical equipment.

Electrodermal activity

Some specialised wearables measure changes in the electrical conductance of the skin, which are influenced by sweat-gland activity.

These measurements can help identify physiological arousal, but they cannot independently diagnose anxiety, psychological illness or another specific physiological condition.

4.2 How AI identifies changes before symptoms appear

The real potential of wearable AI is not necessarily a single unusual reading.

It is the ability to examine a person's measurements over time.

Imagine someone whose normal resting heart rate is relatively stable.

Over several days, their resting heart rate begins increasing. At the same time, their sleep becomes fragmented, their overnight breathing rate changes and their daily movement decreases.

Any one of these measurements could have an innocent explanation.

Perhaps they exercised more than usual. Perhaps they slept poorly. Perhaps they travelled or experienced unusual stress.

But an algorithm can compare the combination with that person's historical baseline.

This is called personalised baseline monitoring.

Instead of comparing everyone with the same population-wide threshold, the algorithm asks:

Is this person's current physiological pattern significantly different from their own normal pattern?

That distinction matters because two healthy people can have very different resting heart rates, activity levels and sleep characteristics.

A personalised algorithm may recognise a meaningful change even when an individual measurement remains inside a conventional reference range.

However, a change from baseline is a warning signal, not proof of illness.

4.3 Why continuous monitoring can reveal hidden patterns

A conventional medical measurement is often a short observation.

A wearable can generate hundreds or thousands of measurements over an extended period.

This provides opportunities to detect:

Repeated irregular heart rhythms.
Changes in resting heart rate.
Unusual overnight breathing patterns.
Reduced physical activity.
Changes in sleep behaviour.
Gradual physiological deterioration.

The advantage is particularly relevant for conditions that fluctuate.

A person may have an irregular heartbeat for several minutes and then return to a normal rhythm. A short examination performed several hours later might not capture the event.

A wearable that monitors repeatedly has a greater opportunity to identify it.

But continuous measurement also introduces noise. The device may be poorly positioned, the sensor may lose contact with the skin, and physical activity can distort readings.

More data does not automatically mean more accurate information.

5. What Does the Scientific Evidence Say About Wearable Disease Detection?

There is a growing body of research examining whether physiological changes recorded by wearables can identify health problems earlier.

Some applications have more convincing evidence than others.

5.1 Detecting abnormal heart rhythms

One of the best-known examples is atrial fibrillation, commonly called AFib.

Atrial fibrillation is an irregular heart rhythm that can increase the risk of blood clots and stroke.

The difficulty is that it can occur intermittently. Someone may experience an episode without noticing anything unusual.

A smartwatch can use PPG measurements to identify an irregular pulse pattern. Some devices can also record an ECG tracing for further examination.

The landmark Apple Heart Study, published in the New England Journal of Medicine in 2019, investigated this possibility.

The study enrolled 419,297 participants.

During a median monitoring period of 117 days:

2,161 participants, approximately 0.52% of the total, received irregular-pulse notifications.
Among 450 notified participants who returned an analysable ECG patch, 34% had atrial fibrillation recorded on the patch.
The positive predictive value for a subsequent irregular-pulse notification occurring alongside atrial fibrillation on ECG was 84%.

The results demonstrated that a consumer smartwatch could identify signals associated with an important cardiac condition on a large scale.

However, the researchers also highlighted an important complication: the ECG patches were generally applied around 13 days after the initial notification.

Because atrial fibrillation can be intermittent, a later ECG recording might not capture the original episode.

The study therefore supports the usefulness of wearable monitoring, but it does not mean that every irregular-pulse notification establishes a diagnosis.

5.2 Can wearables detect infections before someone feels ill?

This is another fascinating research direction.

When the immune system responds to an infection, the body can undergo measurable physiological changes.

These may include:

An increase in resting heart rate.
Changes in heart-rate variability.
Higher respiratory rates.
Changes in skin temperature.
Alterations in sleep.
Reduced physical activity.

The important insight is that these changes may occur before a person recognises familiar symptoms.

Researchers have investigated whether machine-learning algorithms can combine these signals to identify possible infection episodes.

A review published in Annual Review of Biomedical Engineering examined research into wearable monitoring of viral infections. It described evidence that physiological and behavioural changes may occur before symptom onset, while also emphasising that reliable real-world infection detection had not yet been established.

A particularly relevant study appeared in The Lancet Digital Health in August 2024.

Called DETECT-AHEAD, the decentralised randomised trial investigated whether wearable sensor signals and reported symptoms could be used to prompt people to take at-home tests for respiratory viruses.

Participants received Fitbit Sense devices, and researchers investigated whether changes in physiological measurements could help trigger testing for SARS-CoV-2 and respiratory syncytial virus.

The study demonstrated the feasibility of this approach, but also identified participation and performance barriers that would need to be addressed before large-scale implementation.

The distinction is important.

A smartwatch might recognise that someone's body is behaving differently.

It cannot necessarily determine whether the cause is influenza, COVID-19, another infection, stress, medication or a completely different physiological process.

The wearable can suggest when a more specific test might be useful. The actual diagnostic test must establish what is happening.

6. AI-Powered Glaucoma Testing: Looking for Damage Before Vision Changes

Glaucoma is a group of eye conditions that can damage the optic nerve.

The optic nerve carries visual information from the eye to the brain. Damage to this structure can gradually reduce vision and may eventually cause blindness.

One difficulty is that glaucoma can develop without obvious early symptoms.

People may not notice gradual changes in their peripheral vision until significant damage has occurred.

This makes screening and early assessment particularly important.

6.1 What does an automated glaucoma test measure?

Several different measurements can contribute to glaucoma assessment.

Fundus photography

A camera captures an image of the back of the eye, including the optic nerve head and surrounding retinal structures.

AI software can analyse this image for patterns associated with optic nerve damage.

Optical coherence tomography (OCT)

OCT uses reflected light to create detailed cross-sectional images of retinal structures.

It can help measure the thickness of the retinal nerve fibre layer and other anatomical features.

Visual field testing

This evaluates how well a person can detect objects or points of light across different areas of their field of vision.

Glaucoma can cause characteristic patterns of visual field loss.

Intraocular pressure measurement

Tonometry measures pressure inside the eye.

Elevated pressure is an important risk factor, but pressure alone cannot establish whether glaucoma is present.

6.2 How AI analyses eye images

AI systems can be trained using large collections of retinal photographs reviewed by experienced eye specialists.

The algorithm learns to recognise characteristics such as:

Changes in the optic disc.
The relationship between the optic cup and optic disc.
Retinal nerve fibre layer abnormalities.
Structural patterns associated with glaucoma.

A 2026 study published in the journal Eye investigated an AI-assisted glaucoma screening system using fundus photographs.

The researchers evaluated an independent test cohort and reported sensitivity of approximately 90.3% and specificity of approximately 82.1% for their combined model.

The system was designed to identify abnormal features and trigger referrals rather than independently establish a complete clinical diagnosis.

This is a promising application because automated screening could potentially make preliminary eye assessment more accessible in locations where specialist ophthalmologists are difficult to reach.

However, glaucoma is complex.

A photograph showing an unusual optic nerve does not necessarily establish the disease. A specialist may need to consider eye pressure, visual field results, OCT measurements, medical history and changes over time.

AI can help identify people who need closer examination. It cannot simply turn every abnormal photograph into a confirmed diagnosis.

7. Rapid Infection Diagnostics: When Minutes Can Matter

Infections create a different challenge from cancer screening.

With some infections, waiting for traditional laboratory results can delay important treatment decisions.

This is especially relevant in serious bacterial infections and sepsis.

Sepsis is a life-threatening condition in which the body's response to infection can cause organ dysfunction.

The earlier clinicians understand the likely cause and severity of an infection, the more effectively they may be able to organise appropriate care.

New diagnostic platforms are investigating how to shorten the time between collecting a sample and obtaining useful information.

7.1 What do rapid infection tests actually measure?

There are several approaches.

Antigen tests

These detect specific proteins or other components of a pathogen.

For example, a rapid respiratory virus test may identify viral proteins in a nasal sample.

Molecular tests

These look for genetic material from a pathogen.

Polymerase chain reaction, or PCR, is a familiar example. It amplifies selected genetic sequences so that very small quantities can be detected.

Microbial culture

Traditional culture methods attempt to grow microorganisms from a sample so that laboratory specialists can identify them and sometimes determine which antimicrobial medicines are likely to work.

Host-response tests

These examine how the patient's immune system is reacting.

Instead of searching directly for a bacterium or virus, they measure biological changes in the patient's own cells.

This last category is especially interesting for AI.

7.2 An example: the AI-assisted TriVerity blood test

A study published in Nature Medicine in September 2025 examined an AI-assisted blood-testing system called TriVerity.

The technology combines molecular measurement and machine learning.

It uses isothermal amplification to measure 29 messenger RNA molecules associated with the body's immune response.

An algorithm then produces three scores:

The likelihood of bacterial infection.
The likelihood of viral infection.
The likelihood of needing critical-care interventions within seven days.

The test takes approximately 30 minutes using its cartridge-based laboratory instrument.

The researchers evaluated the system in the SEPSIS-SHIELD study, which included 1,222 patients with valid test results.

The reported area under the receiver operating characteristic curve was:

Assessment	Reported AUROC
Bacterial infection	0.83
Viral infection	0.91
Illness severity	0.78

These results showed that the system could provide useful information about infection type and severity in the studied emergency-care population.

The authors also compared its performance with commonly used indicators, including C-reactive protein, procalcitonin and white blood cell counts.

The study reported improved discrimination for the bacterial and viral infection scores compared with these conventional biomarkers.

There is an important difference between this example and a multi-cancer screening test.

TriVerity was evaluated in people who already had suspected acute infection or sepsis. It is not a general-purpose test for screening healthy populations.

It also measures the host response rather than identifying every individual microorganism.

Its scores support clinical interpretation; they do not eliminate the need to consider the patient's examination, laboratory findings and clinical circumstances.

7.3 The race towards faster blood-based diagnostics

Other research is exploring how to identify pathogens directly from blood.

In August 2026, researchers reported a platform called STREAM in Science Advances.

The approach combines pathogen enrichment with single-cell analysis and molecular identification techniques.

In its reported evaluation, pathogen identification in 104 positive blood-culture samples showed 96.15% concordance with clinical laboratory results. The platform also reported full diagnostic results within approximately 6.75 to 17 hours.

These are research findings, not evidence that every hospital can already replace conventional blood cultures with this platform.

The larger goal is to make infection testing faster without sacrificing the reliability needed for treatment decisions.

The US Centers for Disease Control and Prevention explains a related distinction in respiratory testing: antigen tests usually produce faster results, while molecular tests such as PCR are generally more sensitive. A negative antigen result therefore does not always exclude infection.

8. Detection Versus Diagnosis: The Most Important Difference

This is the central concept behind the entire field.

The words detection, screening, prediction and diagnosis are sometimes used interchangeably in marketing. Scientifically, they describe different things.

Term	What it means	Example
Monitoring	Repeatedly measuring biological information	A watch tracking heart rate
Screening	Looking for possible disease before symptoms appear	A multi-cancer blood test
Detection	Identifying a signal or abnormal pattern	AI flags unusual DNA methylation
Risk prediction	Estimating the probability of a future event	A model estimates infection severity
Diagnosis	Establishing what condition is actually present	A clinician confirms cancer using appropriate investigations

Consider a hypothetical example.

A blood test identifies a molecular pattern associated with pancreatic cancer.

The system reports a positive result and estimates that the signal may have originated in the pancreas.

What happens next?

The medical team needs to investigate.

Depending on the circumstances, further testing might involve imaging, additional laboratory investigations and tissue sampling.

If a biopsy is appropriate, a pathologist examines the tissue for evidence of cancer.

Only after the available evidence has been evaluated can the medical team establish the diagnosis.

The original blood test identified a signal. It did not independently establish the disease.

The same principle applies to wearables.

A watch detects an irregular heartbeat. A medical ECG and clinical evaluation may be needed to confirm the nature of the rhythm.

An AI eye-screening system identifies an abnormality in a retinal image. A comprehensive ophthalmological assessment is needed to establish whether glaucoma is present.

The distinction is not a weakness of AI.

It is how responsible diagnostic medicine works.

Why this distinction matters to patients and healthcare systems

If a screening result is presented as a diagnosis, people may experience unnecessary fear.

If a negative screening result is presented as proof of perfect health, someone may develop false reassurance.

If a predictive score is treated as certainty, healthcare professionals may make decisions that are not justified by the available evidence.

The most useful systems communicate uncertainty clearly.

They explain what was measured, what the algorithm detected, how confident the result is and what additional evidence is needed.

9. Why Early Detection Is Not Always Better

It may seem obvious that discovering a disease earlier must always be beneficial.

But medical screening has a more complicated relationship with time.

9.1 False positives

A false positive occurs when a test indicates that a disease may be present, but subsequent investigation does not confirm it.

This can lead to:

Anxiety and uncertainty.
Additional medical appointments.
Imaging examinations.
Further blood tests.
Invasive procedures.
Financial costs.

A test used in a large population must be evaluated not only by its sensitivity and specificity but also by the number of people who will receive positive results without having the target disease.

9.2 False negatives

A false negative occurs when the test fails to identify a disease that is actually present.

This is particularly important for early cancer detection.

A tumour may be too small to release enough detectable material. It may release molecular material that the assay does not measure. Its biological characteristics may also differ from those represented in the algorithm's training data.

A negative result therefore cannot automatically exclude disease.

9.3 Overdiagnosis

Overdiagnosis is another important problem.

Some diseases develop so slowly that they would never have caused symptoms or shortened a person's life.

If screening identifies these abnormalities, treatment may be unnecessary.

The person may experience the physical and emotional consequences of a disease label and potentially undergo treatment that offers little or no benefit.

This is why the success of a screening programme cannot be measured simply by counting how many abnormalities it discovers.

Researchers need to examine whether the programme reduces serious illness, complications or deaths while keeping unnecessary interventions under control.

The National Cancer Institute discusses these issues in its explanation of cancer screening risks and benefits.

10. The Technical Challenges AI Healthcare Must Overcome

Even sophisticated algorithms face problems when they move from research laboratories into everyday healthcare.

10.1 Biological differences between people

Human bodies are not identical.

Age, genetics, medication, lifestyle, existing conditions and environmental exposure can influence biological measurements.

An algorithm trained on one population may not perform equally well in another.

This is why independent validation across different populations is essential.

10.2 The problem of noisy data

Wearables operate in uncontrolled environments.

A person may move their wrist, sweat, sleep in an unusual position or wear a device too loosely.

These factors can influence the quality of the signal.

Laboratory blood tests also face challenges, including sample handling, contamination, biological variability and measurement differences between laboratories.

AI cannot reliably recover information that was never measured correctly.

10.3 Data privacy

Wearables can collect highly personal information.

Continuous heart-rate measurements, sleep patterns, movement records, location information and other biological signals can reveal details about everyday behaviour.

Blood-testing platforms can also generate sensitive molecular information.

Healthcare organisations and technology companies therefore need strong data-protection systems, clear consent procedures and responsible policies for storing and sharing medical information.

10.4 Algorithmic bias

If a training dataset contains too few examples from certain groups, the model may produce less reliable predictions for those populations.

This is especially important when a system is intended for widespread use.

An AI screening product should be tested in the populations that will actually use it, not simply on the dataset on which it was developed.

10.5 Alert fatigue

Imagine receiving a notification every week telling you that your body has changed.

After repeated warnings that lead nowhere, you may begin ignoring them.

This is called alert fatigue.

A useful medical AI system needs to balance sensitivity with the number and importance of the alerts it generates.

It must identify meaningful changes without overwhelming users and healthcare professionals with noise.

11. Modular Health Wearables: Why the Next Generation May Look Different

Traditional consumer wearables are usually designed around a fixed combination of sensors.

A smartwatch may include optical heart-rate monitoring, an accelerometer, temperature-related sensors and ECG functionality.

However, not every health-monitoring task requires all these components.

Modular wearables explore a more flexible approach.

Instead of relying on one standard device, a monitoring system could combine interchangeable or specialised components.

For example:

A cardiac module could prioritise electrical heart signals.
A temperature module could monitor changes over time.
A movement module could evaluate mobility and activity.
A biochemical sensor could investigate selected substances in sweat or another bodily fluid.
A communication module could transmit measurements to a secure clinical platform.

Some experimental wearable biosensors investigate sweat, saliva, tears and interstitial fluid.

These technologies aim to measure biochemical information rather than relying exclusively on physical measurements such as pulse and movement.

This is a significant distinction.

A conventional smartwatch might estimate that a person's physiological state has changed.

A biochemical wearable could eventually provide more direct information about selected chemical processes.

However, there are difficult engineering problems.

Sensors must collect enough biological material, maintain stable measurements, avoid contamination and function reliably across different skin types, temperatures and activity levels.

A sensor that works perfectly in a controlled laboratory experiment may behave differently when worn throughout an ordinary day.

The 2026 wearable-sensor research landscape includes promising developments in microfluidics, flexible materials and biochemical monitoring, but many technologies remain under development.

12. How Blood Tests and Wearables Could Work Together

One of the most interesting possibilities is combining different sources of biological information.

Consider three layers of monitoring.

Layer one: continuous physiological observation

A wearable collects measurements such as heart rate, temperature, sleep and movement.

Layer two: targeted biological testing

If a clinically relevant change is identified, a laboratory test may examine selected proteins, genetic material or immune-response markers.

Layer three: clinical interpretation

A healthcare professional evaluates the results alongside medical history, physical examination and any necessary imaging or other investigations.

This approach could create a more connected healthcare pathway.

A wearable might identify an unusual change. A targeted blood test might investigate a biological explanation. A clinician might then decide whether additional examination is necessary.

It is important to stress that this is a potential model for future healthcare, not a universally established diagnostic pathway.

The technology will only be useful if the measurements are reliable, the alerts are actionable and the follow-up system is accessible.

The most important innovation may not be a single revolutionary device.

It may be the ability to connect different measurements into a coherent clinical picture.

13. What Is Already Established, and What Remains Uncertain?

The distinction between current evidence and future expectations is essential.

Technology	What is established	What remains uncertain
AI-supported cancer blood testing	Tests can identify cancer-associated molecular patterns	Whether widespread screening reduces cancer mortality
Smartwatch cardiac monitoring	Certain devices can identify signals associated with AFib	How much broad population monitoring improves long-term outcomes
Wearable infection monitoring	Physiological changes can be associated with infection	Reliable diagnosis before symptoms in everyday populations
AI glaucoma screening	Algorithms can identify suspicious retinal features	Whether stand-alone automated screening improves population outcomes
Rapid infection diagnostics	Molecular and host-response tests can provide useful information quickly	How consistently new platforms improve clinical outcomes across hospitals
Modular biochemical wearables	Experimental sensors can measure selected biological substances	Long-term accuracy, affordability and clinical usefulness

The NHS-Galleri trial is particularly important because it demonstrates why clinical outcome evidence matters.

Even a technology that identifies genuine cancer signals must still demonstrate that using it improves meaningful health outcomes.

Likewise, promising AI performance in an eye-image study does not automatically prove that the same system will work equally well across different populations, cameras and healthcare settings.

Future research needs larger studies, longer follow-up, independent validation and evidence that the technology improves decisions rather than simply generating more data.

14. What Could Healthcare Look Like by 2030?

The future of medical monitoring is likely to involve a combination of technologies rather than one device replacing everything else.

Laboratories may increasingly combine molecular measurements with AI-assisted interpretation.

Wearables may become more specialised, with different sensor configurations for particular medical applications.

Remote monitoring could become more useful for people who live far from hospitals or specialist clinics.

Automated imaging systems could help identify suspicious findings in areas where access to experienced specialists is limited.

Rapid diagnostic platforms could shorten the time required to distinguish between certain types of infection.

But technological progress will not remove the need for medical expertise.

A highly accurate algorithm still needs a reliable measurement. A reliable measurement still needs clinical interpretation. And an early warning only becomes valuable when an appropriate next step is available.

There is also an important economic question.

Will these systems become affordable enough to benefit people outside wealthy healthcare systems?

A technology that works only in expensive private laboratories will not deliver the same public-health benefits as a reliable test that can be deployed in ordinary clinics.

Accessibility, affordability and healthcare infrastructure will therefore be as important as algorithmic accuracy.

Conclusion: The Biggest Breakthrough May Be Seeing the Warning Earlier

Artificial intelligence is changing how scientists examine the human body.

Blood tests can now investigate molecular patterns that would be difficult to interpret using a single conventional measurement. Wearables can collect physiological information continuously. Automated imaging systems can identify suspicious eye structures. Rapid infection platforms can combine molecular testing with algorithms to provide clinicians with additional information.

These technologies are creating new opportunities to identify biological changes before they become obvious.

But the most important lesson is that early detection is only the beginning.

A positive blood test does not automatically mean cancer. An unusual smartwatch reading does not automatically mean heart disease. An abnormal eye image does not independently establish glaucoma. A predictive infection score does not replace clinical assessment.

The future of healthcare will depend on connecting early signals to accurate confirmation, appropriate treatment and measurable improvements in people's lives.

The real promise of medical AI is not that machines will suddenly know everything about the human body.

It is that they may help healthcare professionals notice important changes that would otherwise remain hidden until much later.

And sometimes, in medicine, noticing something earlier can make all the difference.

Key Takeaways

AI blood tests measure biological signals. These can include circulating tumour DNA, DNA methylation, RNA, proteins and other biomarkers.
AI identifies patterns rather than magically discovering diseases. Its predictions depend on laboratory measurements, training data and clinical validation.
Multi-cancer blood tests are promising but not proven replacements for conventional screening. The 2026 NHS-Galleri trial did not meet its primary endpoint of reducing overall stage III and IV cancer diagnoses.
Wearables measure physiological signals. Common technologies include PPG, ECG, accelerometers, temperature sensors and pulse oximetry.
Personalised monitoring can identify changes from an individual's baseline. However, a change does not necessarily indicate illness.
AI-assisted glaucoma screening can help identify suspicious eye images. A complete diagnosis still requires appropriate ophthalmological assessment.
Rapid infection diagnostics use several approaches. These include antigen detection, molecular testing and analysis of the body's immune response.
Detection and diagnosis are different. An early warning generally requires additional investigation before a condition can be confirmed.
False positives, false negatives and overdiagnosis remain important risks.
The future is likely to involve connected systems. Wearables, laboratory testing, medical imaging and clinical expertise may work together to support earlier healthcare decisions.

Frequently Asked Questions (FAQ)

1. Can AI detect cancer through a blood test?

Yes, certain multi-cancer early detection tests can identify molecular patterns associated with cancer in blood samples. They may examine circulating tumour DNA, DNA methylation, fragmentation patterns and proteins. However, a positive result does not independently confirm cancer. Further diagnostic investigations are necessary.

2. Can a blood test detect several cancers at once?

Some multi-cancer detection tests are designed to search for signals associated with several cancer types using one blood sample. Their capabilities vary, and none should be assumed to detect every cancer. The NHS-Galleri trial demonstrated that such testing can identify cancer signals, but its primary clinical outcome was not achieved.

3. Can a smartwatch detect illness before symptoms appear?

A smartwatch may identify physiological changes associated with an illness, including changes in heart rate, sleep, temperature and activity. Research suggests that these changes can sometimes occur before symptoms. However, a smartwatch cannot reliably identify every infection or disease from these measurements.

4. How does AI detect an irregular heartbeat?

AI-supported systems analyse signals collected through optical pulse sensors or ECG electrodes. They examine heartbeat intervals and electrical patterns to identify characteristics associated with abnormal rhythms such as atrial fibrillation. A notification is a screening signal, not necessarily a confirmed diagnosis.

5. Can wearables detect infections?

Wearables may identify changes associated with the body's response to infection. Researchers have investigated heart rate, heart-rate variability, breathing, sleep, temperature and physical activity. However, these measurements are not specific enough to identify the exact pathogen. A targeted laboratory test is needed to investigate the cause.

6. What is the difference between early detection and diagnosis?

Early detection means identifying a possible disease-related signal or abnormality. Diagnosis means establishing what condition is actually present through appropriate medical evaluation and testing. Screening technologies generally identify people who may need further investigation.

7. Can AI detect glaucoma?

AI can analyse retinal photographs and other eye-imaging information to identify features associated with glaucoma. Some research systems have demonstrated promising sensitivity and specificity. However, diagnosis requires broader clinical assessment, potentially including eye pressure measurements, OCT imaging and visual field testing.

8. Are AI cancer blood tests approved by the FDA?

As of November 5, 2026, the US National Cancer Institute states that no multi-cancer detection tests have received FDA authorisation. Some are offered as laboratory-developed tests. Regulatory requirements differ between countries, and clinical usefulness must be assessed separately from regulatory status.

9. Can a negative AI blood test guarantee that someone does not have cancer?

No. Some cancers may not release sufficient detectable material into the blood, and some molecular patterns may not be recognised by a particular test. A negative result cannot guarantee the absence of cancer or replace established screening programmes.

10. Why are false-positive results a problem?

A false positive can suggest that someone has a disease when subsequent investigations find no evidence of it. This may cause anxiety and lead to unnecessary medical procedures, additional expenses and further testing.

11. Will AI replace doctors and laboratory specialists?

There is no convincing basis for assuming that AI will completely replace medical professionals. AI can assist with pattern recognition, screening, risk assessment and data interpretation. Clinical decisions still require appropriate evidence, medical judgement and patient-specific context.

12. What is a modular health wearable?

A modular health wearable is a monitoring system that can combine different sensor components according to the health information being measured. These components might monitor cardiac activity, movement, temperature or selected biochemical substances. The approach aims to make monitoring more adaptable to different clinical needs.

13. What is the biggest challenge facing AI disease detection?

One of the biggest challenges is demonstrating that detecting abnormalities earlier actually improves health outcomes. Researchers must establish accuracy, reduce false alarms, validate algorithms across different populations and show that the technology leads to effective follow-up and treatment.

14. Could AI blood tests and wearables become part of routine healthcare?

They could become increasingly integrated into healthcare, particularly for monitoring, screening and clinical decision support. However, widespread adoption will depend on evidence, affordability, regulatory requirements, privacy protections and the ability of healthcare systems to respond to the information they generate.

Photographs and Image Credits

Photograph 1: Blood samples in a medical laboratory

View original photograph

Caption: Blood collection tubes being handled in a laboratory. Image source: National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH).

Photograph 2: Smartwatch and continuous health monitoring